Monitor for imminent ATM share sales given the clinical trial setbacks and the immediate availability of the $150 million ATM program. The stock is likely to face significant downward pressure when sales begin, as the offering size exceeds the company's current market value.
Price Chart
Executive Summary
Aardvark Therapeutics has filed an S-3 shelf registration allowing it to raise up to $400 million through various securities offerings, including a $150 million ATM program with Piper Sandler. This signals a need for capital, especially after pausing key clinical trials due to safety concerns, which increases the likelihood of near-term share issuance and dilution.
Key Financial Metrics
Key Facts
- Company filed S-3 shelf registration for up to $400 million in securities offerings
- $150 million of the shelf is allocated to an ATM program with Piper Sandler for common stock
- Clinical trials (HERO, POWER, STRENGTH) paused due to safety concerns in healthy volunteer study
- Market cap is $89 million, making the $150 million offering size extremely dilutive (169% of current market cap)
- Company has $126.4 million in cash as of September 30, 2025, but is burning cash rapidly ($37.4 million in 9 months)
Financial Impact
$150 million in potential dilution from ATM program, representing 169% of current $89 million market cap
Risk Factors
- Significant dilution from ATM share sales
- Clinical trial setbacks may delay or prevent product approval
- Cash burn rate may necessitate additional fundraising
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-119973 |
| Document: ck0001774857-ex4_2.htm | 0001193125-26-119973 |
| Document: ck0001774857-ex1_2.htm | 0001193125-26-119973 |
| CONTEXT: 10-Q (2025-11-13) | 0001193125-25-280260 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | Press Release | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 8, 2026 18d ago | 3 | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Oct 8, 2026 18d ago | 8-K | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Aug 12, 2026 10w ago | Institutional Cluster | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | 8-K | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | Press Release | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.64 $3.90 | ▲ +7.14% | ▲ +6.60% | $1.08 (−70.33%) |
May 14, 2026 23w ago | Press Release | $4.57 $4.36 | ▲ +4.60% | ▲ +4.53% | $1.08 (+76.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers